Breast cancer vaccine - Anixa Biosciences/Cleveland Clinic
Alternative Names: Alpha-lactalbumin vaccine - Anixa Biosciences/Cleveland ClinicLatest Information Update: 11 Jun 2025
At a glance
- Originator Cleveland Clinic
- Developer Anixa Biosciences; Cleveland Clinic
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Triple negative breast cancer
Most Recent Events
- 02 Jun 2025 Breast cancer vaccine is still in phase-I development in Triple-negative-breast-cancer in USA (SC, Injection)
- 02 Jun 2025 Anixa Biosciences completes enrolment in its phase-I trial in Triple-negative-breast cancer in USA (SC) (NCT04674306)
- 09 Apr 2025 USPTO issues notice of allowance for a patent covering breast cancer vaccine technology